Novartis AG (NVS)
158.02
-0.84
(-0.53%)
USD |
NYSE |
Aug 24, 16:00
158.00
-0.02
(-0.01%)
Pre-Market: 20:00
Novartis Enterprise Value : 330.99B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 330.99B |
| August 21, 2026 | 332.53B |
| August 20, 2026 | 327.73B |
| August 19, 2026 | 335.18B |
| August 18, 2026 | 324.64B |
| August 17, 2026 | 319.92B |
| August 14, 2026 | 317.92B |
| August 13, 2026 | 319.46B |
| August 12, 2026 | 320.56B |
| August 11, 2026 | 324.75B |
| August 10, 2026 | 328.74B |
| August 07, 2026 | 327.90B |
| August 06, 2026 | 324.02B |
| August 05, 2026 | 324.44B |
| August 04, 2026 | 322.30B |
| August 03, 2026 | 323.03B |
| July 31, 2026 | 327.57B |
| July 30, 2026 | 331.76B |
| July 29, 2026 | 332.47B |
| July 28, 2026 | 334.34B |
| July 27, 2026 | 327.50B |
| July 24, 2026 | 325.48B |
| July 23, 2026 | 327.55B |
| July 22, 2026 | 321.95B |
| July 21, 2026 | 323.39B |
| Date | Value |
|---|---|
| July 20, 2026 | 315.51B |
| July 17, 2026 | 323.19B |
| July 16, 2026 | 321.31B |
| July 15, 2026 | 317.77B |
| July 14, 2026 | 316.97B |
| July 13, 2026 | 322.48B |
| July 10, 2026 | 323.72B |
| July 09, 2026 | 324.77B |
| July 08, 2026 | 325.77B |
| July 07, 2026 | 329.18B |
| July 06, 2026 | 326.36B |
| July 02, 2026 | 334.43B |
| July 01, 2026 | 323.89B |
| June 30, 2026 | 328.61B |
| June 29, 2026 | 341.13B |
| June 26, 2026 | 336.97B |
| June 25, 2026 | 336.42B |
| June 24, 2026 | 332.60B |
| June 23, 2026 | 333.10B |
| June 22, 2026 | 324.61B |
| June 18, 2026 | 321.08B |
| June 17, 2026 | 328.33B |
| June 16, 2026 | 328.42B |
| June 15, 2026 | 329.63B |
| June 12, 2026 | 332.51B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Roche Holding AG | -- |
| AstraZeneca PLC | 543.37B |
| Johnson & Johnson | 685.82B |
| Eli Lilly & Co. | 1.220T |
| Merck & Co., Inc. | 418.70B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.259B |
| Revenue (Quarterly) | 14.42B |
| Total Expenses (Quarterly) | 11.15B |
| EPS Diluted (Quarterly) | 1.706 |
| Gross Profit Margin (Quarterly) | 74.47% |
| Profit Margin (Quarterly) | 22.61% |
| Earnings Yield | 4.19% |
| Operating Earnings Yield | 5.33% |
| Normalized Earnings Yield | 4.503 |